FAP PET identifies earlycardiac molecular changesinduced by doxorubicin chemotherapy
Open Access
- 21 October 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (23)
Abstract
Anthracycline chemotherapy, widely used in cancer treatment, poses a significant risk of cardiotoxicity that results in functional decline. Current diagnostic methods poorly predict cardiotoxicity because they do not detect early damage that precedes dysfunction. Positron emission tomography (PET) is well suited to address this need when coupled with suitable imaging biomarkers. We used PET to evaluate cardiac molecular changes in male C57BL/6J mice exposed to doxorubicin (DOX). These mice initially developed cardiac atrophy, experienced functional deficits within 10 weeks of treatment, and developed cardiac fibrosis by 16 weeks. Elevated cardiac uptake of [ 68 Ga]Ga-FAPI-04, a PET tracer targeting fibroblast activation protein α (FAP), was evident by 2 weeks and preceded the onset of functional deficits. Cardiac PET signal correlated with FAP expression and activity as well as other canonical indicators of cardiac remodeling. By contrast, cardiac uptake of [ 18 F]DPA-714 and [ 18 F]MFBG, which target translocator protein 18 kDa and the norepinephrine transporter, respectively, did not differ between the DOX animals and their controls. These findings identify FAP as an early imaging biomarker for DOX-induced cardiac remodeling in males and support the use of FAP PET imaging to detect some cancer patients at risk for treatment-related myocardial damage before cardiac function declines.Keywords
Funding Information
- Instituto Nacional de Cancerología (R21CA246409-01)
- Instituto Nacional de Cancerología (P30CA008748)
This publication has 76 references indexed in Scilit:
- Early detection of anthracycline-induced cardiotoxicity using [68 Ga]Ga-FAPI-04 imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activityEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- PET Tracers for Imaging Cardiac Function in Cardio-oncologyCurrent Cardiology Reports, 2022
- Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targetsHeart Failure Reviews, 2020
- Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumourEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Anthracycline Chemotherapy and CardiotoxicityCardiovascular Drugs and Therapy, 2017
- Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancerCochrane Database of Systematic Reviews, 2014
- Late anthracycline cardiotoxicity after childhood cancerCancer, 2003
- Assessment of anthracycline-related myocardial adrenergic derangement by [123i]metaiodobenzylguanidine scintigraphyEuropean Journal of Cancer, 1995
- Early changes in human myocardial nuclei after doxorubicinCancer, 1983